7:01 AM
Nov 13, 2017
 |  BC Extra  |  Company News

Excision licenses new CRISPR IP

Excision BioTherapeutics Inc. (Philadelphia, Pa.) obtained exclusive licenses to IP from University of California Berkeley covering new CRISPR-based gene editing technologies. The licenses include the use of CRISPR systems using CasX, CasY and ARMAN endonucleases to treat viral infectious diseases. Excision also has rights to sub-license...

Read the full 208 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >